  Drug repurposing has attracted increasing attention from both the
pharmaceutical industry and the research community. Many existing computational
drug repurposing methods rely on preclinical data (e.g., chemical structures,
drug targets), resulting in translational problems for clinical trials. In this
study, we propose a clinical connectivity map framework for drug repurposing by
leveraging laboratory tests to analyze complementarity between drugs and
diseases. We establish clinical drug effect vectors (i.e., drug-laboratory test
associations) by applying a continuous self-controlled case series model on a
longitudinal electronic health record data. We establish clinical disease sign
vectors (i.e., disease-laboratory test associations) by applying a Wilcoxon
rank sum test on a large-scale national survey data. Finally, we compute a
repurposing possibility score for each drug-disease pair by applying a dot
product-based scoring function on clinical disease sign vectors and clinical
drug effect vectors. We comprehensively evaluate 392 drugs for 6 important
chronic diseases (e.g., asthma, coronary heart disease, type 2 diabetes, etc.).
We discover not only known associations between diseases and drugs but also
many hidden drug-disease associations. Moreover, we are able to explain the
predicted drug-disease associations via the corresponding complementarity
between laboratory tests of drug effect vectors and disease sign vectors. The
proposed clinical connectivity map framework uses laboratory tests from
electronic clinical information to bridge drugs and diseases, which is
explainable and has better translational power than existing computational
methods. Experimental results demonstrate the effectiveness of the proposed
framework and suggest that our method could help identify drug repurposing
opportunities, which will benefit patients by offering more effective and safer
treatments.
